Praxis Precision Medicines
PRAX
95 hedge funds and large institutions have $106M invested in Praxis Precision Medicines in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 37 increasing their positions, 20 reducing their positions, and 27 closing their positions.
764% more call options, than puts
Call options by funds: $1.22M | Put options by funds: $141K
85% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.33% less ownership
Funds ownership: 6.65% → 6.32% (-0.33%)
8% less funds holding
Funds holding: 103 → 95 (-8)
22% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 27
77% less capital invested
Capital invested by funds: $463M → $106M (-$358M)
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$26.4M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$17.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.86M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$5.9M |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$5.28M |
Top Sellers
PRAX Hedge Fund Activity: Q2 2022 in Review
95 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q2 2022, worth a combined $106M — down 77% from $463M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of PRAX and 21 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 37 added.
The largest buyer was State Street, adding an estimated $26.4M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $34M sold.
- 95 institutional investors held Praxis Precision Medicines (PRAX) as of Q2 2022, down from 103 in Q1 2022.
- Funds reported $106M of Praxis Precision Medicines stock for Q2 2022, down 77% quarter-over-quarter.
- 21 funds opened new Praxis Precision Medicines positions in Q2 2022 and 27 closed out, a net change of -6 holders.
- The largest Praxis Precision Medicines buyer in Q2 2022 was State Street, an estimated $26.4M added.
- The largest Praxis Precision Medicines seller in Q2 2022 was Janus Henderson Group, an estimated $34M sold.
Based on aggregated 13F filings for Q2 2022.